תבנית:תרופה/קנסידס 70 מ"ג - Cancidas 70 mg
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |
|---|---|
| ×§×××¦× ×¤×¨××§×××××ת (ATC4) | J02AX Other antimycotics for systemic use |
| ×ר××× ×¤×¢×× (ATC5) | Â
|
| צ×רת ××ª× | ת××-×ר××× - I.V |
| צ×רת ××× ×× | ×××§× ××××שת ××קפ×× ×××× ×ª תר××× ×××× ×¤××××, LYOPHILIC POWDER FOR CONCENTRATED INFUSION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× |
| ×ת×××× | Cancidas is indicated in adults and pediatric patients (3 months and older) for:- Empirical therapy for presumed fungal infections in febrile, neutropenic patients.- Treatment of candidemia and the following candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. Cancidas has not been studied in endocarditis, ostemyelitis, and meningitis due to Candida.- Treatment of esophageal candidiasis.- Treatment of invasive aspergillosis in patients who are refractory to or intolerant to other therapies (i.e. amphotericin B, lipid formulations of amphotericin B, and/or itraconazole). Cancidas has not been studied as initial therapy for invasive aspergillosis.
|
| ת×× ×ת:× ×ª×× × ×¡×/תר×פ×/×§× ×¡××ס 70 ×"× - Cancidas 70 mg | |
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× | |
| ער××× ×××××§×רפ××× | ער××× ×§×©×ר×× ×××××§×רפ××× |
|---|---|
| ×§× ×¡××ס 70 ×"× Â® ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | - |
|---|---|
| ××××¢ ×רשת | - |
| ×©× ××¦×¨× | LABORATORIES MERCK, SHARP & DOHME - CHIBRET, FRANCE |
| ×©× ××¢× ×ר×ש×× | MERCK SHARP & DOHME ISRAEL LTD |
| ר×ש××× | ת×ר×× ××ש×: 10/2001. ר×ש××× ×ת×ר××: 11/2011 |
| ת×ר×× ×¢×××× ××ר×× | 14/05/19 |
××£ ×× × ×צר ×¢× ××× ××× ×××××ר ת×× ×ת ×¢× ×¤×¨×× ×תר×פ×.
- ××£ ×תר×פ×: ×§× ×¡××ס 70 ×"× - Cancidas 70 mg
- ××ר××¡× ××× ×ת ×©× ×¤×¨×× ×תר×פ×: × ××ª× ×ער×× ×ת ××£ ×תר××¤× ××¢××. ×××××× ×××××¤× ×ת:
{{תר×פ×/×§× ×¡××ס 70 ×"× - Cancidas 70 mg}}
×:
{{תר×פ×/×§× ×¡××ס 70 ×"× - Cancidas 70 mg
| ×©× ×פר××ר=×¢×¨× ××ש (××רס ×ת ××¢×¨× ×©×××× ××××ר)
}}
השינוי האחרון נעשה בֹ־26 בדצמבר 2021 ב־14:35